IDO1 and glioblastoma: Overall, these analyses suggest that the measured Ki67 mostly comes from tumor cells in the immune-poor regions, and that co-targeting B7-H3 or IDO-1 in neoadjuvant ICB treatment may potentially improve the treatment outcome for patients with recurrent GBM.